Hubei Jumpcan Pharmaceutical (600566) News

Jichuan Pharmaceutical (600566): Operating performance shows marginal improvement in Q2 2026, with an expanding pipeline of innovative products.

Kaiyuan SecuritiesAug 31 00:00

Jichuan Pharmaceutical (600566) 2026 Interim Report Commentary: Q2 Earnings Recover; Robust Pipeline Bolsters Long-Term Growth

Sinolink SecuritiesAug 30 18:56

Jichuan Pharmaceutical (600566): Earnings Under Temporary Pressure; Optimistic About the Implementation of Innovation and BD-Driven Growth

Shenwan Hongyuan ResearchMay 14 15:51

Jichuan Pharmaceutical (600566): Results in Line with Expectations, Dividend Value Becomes More Prominent

Changjiang SecuritiesMay 10 07:32

Jichuan Pharmaceutical (600566) 2025 Annual Report Commentary: Short-Term Earnings Under Pressure; Focus on the Development of New Products

Guotai Haitong SecuritiesMay 1 00:00

Jichuan Pharmaceutical (600566): Maintaining a High Cash Dividend Payout Ratio While Bolstering Mid- to Long-Term Growth Through Innovative R&D and Strategic Collaborations

SDIC SecuritiesApr 29 20:51

Jichuan Pharmaceutical (600566): Performance Under Temporary Pressure in 2025; BD Partnerships Bolster Future Growth

Open Source SecuritiesApr 29 07:47

Jichuan Pharmaceutical (600566): Strong Q4 2025 Results Driven by High Dividends and BD Catalysts

Great Wall SecuritiesApr 28 12:37

Jichuan Pharmaceutical (600566): Short-Term Earnings Under Pressure, Yet Maintains High Dividend Payout

Guojin SecuritiesApr 23 00:00